REG - Faron Pharma. Oy - Manager's transactions

Faron Pharmaceuticals OyAnnouncement

27/10/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231027:nRSa5828Ra&default-theme=true

RNS Number : 5828R  Faron Pharmaceuticals Oy  27 October 2023

Faron Pharmaceuticals Ltd.

("Faron" or the "Company")

 

Managers' transactions

 

Company announcement, October 27, 2023 at 3:00 pm  (EEST)

Inside Information

TURKU, Finland / BOSTON, Massachusetts - October 27 , 2023 - Faron
Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage
biopharmaceutical company pioneering macrophage reprogramming for effective
anticancer immunotherapies, announces today that John Poulos, a Non-executive
Director of the Company, on October 3, 2023 sold 5,000 ordinary shares in
Faron at a price of €3.7209 per share, and on October 12, 2023, sold 5,000
ordinary shares in Faron at a price of €3.8259 per share. Following these
disposals, John Poulos directly holds 10,000 ordinary shares in the Company,
representing 0.02 per cent. of the Company's issued share capital.

The notification below, which has been made in accordance with the
requirements of the EU Market Abuse Regulation, provides further detail.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         John Poulos

 2   Reason for notification
 a.  Position/Status                                              Non-executive Director
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Faron Pharmaceuticals Oy
 b.  LEI                                                          7437009H31TO1DC0EB42
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares

Identification Code
ISIN: FI4000153309
 b.  Nature of the transaction                                    1)    Disposal of ordinary shares (October 3, 2023)

                                                                  2)    Disposal of ordinary shares (October 12, 2023)
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     1)    €3.7209                                                                                    1)    5,000

     2)    €3.8259                                                                                    2)    5,000

 d.  Aggregated information

     - Aggregated Volume                                          1)    5,000

                                                                  2)    5,000

     - Price                                                      1)    €3.7209

                                                                  2)    €3.8259
 e.  Date of the transaction                                      1)    October 3, 2023

                                                                  2)    October 12, 2023
 f.  Place of the transaction                                     Nasdaq First North Growth Market

 

For more information please contact:

 

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com (mailto:daniel@lifesciadvisors.com)

+1 (617) 430-7576

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at www.faron.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.faron.com%2F&data=05%7C01%7C%7Ca4ae0afa96854c5c5f2a08db771ae20d%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638234729855975666%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FNadoN9wXIGZtfCkFVuLSTXPpNg3%2BBXoRfIQaIPce6k%3D&reserved=0)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPGPWUUPWGGM